Gerwin Heller
Overview
Explore the profile of Gerwin Heller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melhorn P, Tomasich E, Blessing A, Brcic L, Kogler A, Draschl A, et al.
Endocr Pathol
. 2025 Mar;
36(1):6.
PMID: 40072638
Neuroendocrine tumors (NET) of the lung constitute a rare entity of primary lung malignancies that often exhibit an indolent clinical course. Epigenetics-related differences have been described previously for lung NET,...
2.
Kleinberger M, Cifci D, Paiato C, Tomasich E, Mair M, Steindl A, et al.
Acta Neuropathol Commun
. 2025 Feb;
13(1):34.
PMID: 39972401
Background: Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) have increasingly been reported to impact the brain metastatic process of solid tumors. However, data on intra-individual differences between primary tumor and...
3.
Scheiblecker L, Klampfl T, Doma E, Nebenfuehr S, Torres-Quesada O, Strich S, et al.
Cell Death Dis
. 2025 Feb;
16(1):107.
PMID: 39966356
Metabolic reprogramming and cell cycle deregulation are hallmarks of cancer cells. The cell cycle kinase CDK6 has recently been implicated in a wide range of hematopoietic malignancies. We here investigate...
4.
Mair M, Leibetseder A, Heller G, Tomasich E, Muller L, Busse I, et al.
J Neurol
. 2025 Feb;
272(3):210.
PMID: 39954095
Purpose: The prognosis of diffuse gliomas previously classified as "lower-grade" is heterogeneous and complicates clinical decisions. We aimed to investigate the molecular profile of clinical outliers to gain insight into...
5.
Trifinopoulos J, List J, Klampfl T, Klein K, Prchal-Murphy M, Witalisz-Siepracka A, et al.
Haematologica
. 2024 Oct;
PMID: 39385738
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of...
6.
Kieler M, Prammer L, Heller G, Hofmann M, Sperger S, Hanetseder D, et al.
Ann Rheum Dis
. 2024 Jul;
83(11):1465-1479.
PMID: 38986577
Objectives: Bone remodelling is a highly dynamic process dependent on the precise coordination of osteoblasts and haematopoietic-cell derived osteoclasts. Changes in core metabolic pathways during osteoclastogenesis, however, are largely unexplored...
7.
Tomasich E, Muhlbacher J, Woran K, Hatziioannou T, Herac M, Kleinberger M, et al.
Transl Res
. 2024 May;
271:40-51.
PMID: 38734064
The presence of abundant tumor stroma is a prominent characteristic of pancreatic ductal adenocarcinomas (PDAC) that potentially influences disease progression and therapy response. This study aims to investigate immune cell...
8.
Mayer I, Doma E, Klampfl T, Prchal-Murphy M, Kollmann S, Schirripa A, et al.
Blood
. 2024 Apr;
144(2):156-170.
PMID: 38684032
Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and to replenish the hematopoietic system. The cell-cycle kinase cyclin-dependent kinase 6 (CDK6) regulates transcription, whereby it has both...
9.
Ressler J, Tomasich E, Hatziioannou T, Ringl H, Heller G, Silmbrod R, et al.
Target Oncol
. 2024 Feb;
19(2):263-275.
PMID: 38401029
Background: DNA methylation profiles have emerged as potential predictors of therapeutic response in various solid tumors. Objective: This study aimed to analyze the DNA methylation profiles of patients with stage...
10.
Funk M, Heller G, Waidhofer-Sollner P, Leitner J, Steinberger P
Mol Ther
. 2024 Feb;
32(4):982-999.
PMID: 38384128
Chimeric antigen receptors (CARs) equipped with an inhibitory signaling domain (iCARs) have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies. iCARs inhibit T cell activation upon...